Published in Eur J Clin Pharmacol on January 01, 1993
Implementing guidelines and innovations in general practice: which interventions are effective? Br J Gen Pract (1998) 6.99
Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol (2006) 3.56
Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol (1998) 2.32
Percentage of patients with preventable adverse drug reactions and preventability of adverse drug reactions--a meta-analysis. PLoS One (2012) 1.68
Prevalence, nature and potential preventability of adverse drug events - a population-based medical record study of 4970 adults. Br J Clin Pharmacol (2014) 0.96
Prevalence and perceived preventability of self-reported adverse drug events--a population-based survey of 7099 adults. PLoS One (2013) 0.87
Study on drug related hospital admissions in a tertiary care hospital in South India. Saudi Pharm J (2011) 0.84
Prevalence of Drug-Related Emergency Department Visits at a Teaching Hospital in Malaysia. Drugs Real World Outcomes (2015) 0.76
Postgraduate education in clinical pharmacology and therapeutics. Br J Clin Pharmacol (1998) 0.75
Adverse drug events-Analysis of a decade. A Portuguese case-study, from 2004 to 2013 using hospital database. PLoS One (2017) 0.75
The heritability of human longevity: a population-based study of 2872 Danish twin pairs born 1870-1900. Hum Genet (1996) 4.90
Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. J Intern Med (1990) 2.96
[Teratogenic effects of inhalation anesthetics]. Nord Med (1970) 2.65
Ban prehospital randomized studies. Eur J Emerg Med (1997) 2.41
Longevity is moderately heritable in a sample of Danish twins born 1870-1880. J Gerontol (1993) 2.30
The teaching and organisation of clinical pharmacology in European medical schools (W.H.O. Working Group on Clinical Pharmacology). Eur J Clin Pharmacol (1990) 2.07
Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol (1989) 2.04
Quantitative rating of depressive states. Acta Psychiatr Scand (1975) 2.00
A Danish twin study of manic-depressive disorders. Br J Psychiatry (1977) 1.86
Drug related admissions to medical wards: a population based survey. Br J Clin Pharmacol (1992) 1.70
Measures of twin concordance. Acta Genet Stat Med (1967) 1.69
A population-based study of Graves' disease in Danish twins. Clin Endocrinol (Oxf) (1998) 1.67
Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol (1996) 1.60
CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand (2001) 1.59
The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study. Br J Clin Pharmacol (1991) 1.54
The elasticity and the tensile strength of tunica albuginea of the corpora cavernosa. J Urol (1990) 1.52
The Hamilton depression scale. Evaluation of objectivity using logistic models. Acta Psychiatr Scand (1981) 1.43
Biochemical markers of bone metabolism in benign human osteopetrosis: a study of two types at baseline and during stimulation with triiodothyronine. Eur J Endocrinol (1998) 1.42
Helioseismic measurement of solar torsional oscillations. Science (2002) 1.40
Making doctors change. J Intern Med (1996) 1.39
Coronary occlusion in twins. Acta Genet Med Gemellol (Roma) (1971) 1.39
Yellow nail syndrome--the triad of yellow nails, lymphedema and pleural effusions. A review of the literature and a case report. Acta Med Scand (1986) 1.37
Contacts to the health care system prior to suicide: a comprehensive analysis using registers for general and psychiatric hospital admissions, contacts to general practitioners and practising specialists and drug prescriptions. Acta Psychiatr Scand (2000) 1.32
Sparteine oxidation polymorphism in Denmark. Acta Pharmacol Toxicol (Copenh) (1985) 1.27
The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther (1992) 1.26
The Danish twin register. Acta Genet Med Gemellol (Roma) (1968) 1.25
Are young adults with asthma treated sufficiently with inhaled steroids? A population-based study of prescription data from 1991 and 1994. Br J Clin Pharmacol (1996) 1.25
Sparteine oxidation is practically abolished in quinidine-treated patients. Br J Clin Pharmacol (1986) 1.23
Use of sumatriptan in Denmark in 1994-5: an epidemiological analysis of nationwide prescription data. Br J Clin Pharmacol (1997) 1.22
Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology (2003) 1.20
Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. Pharmacol Toxicol (1987) 1.20
The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain (1990) 1.20
Tobacco use, alcohol consumption and infertility. Int J Epidemiol (1983) 1.18
The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin Pharmacol Ther (1992) 1.18
The Danish Twin Register. Dan Med Bull (1996) 1.16
Drug interaction: inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man. Br Med J (1972) 1.15
Untangling genetic influences on smoking, body mass index and longevity: a multivariate study of 2464 Danish twins followed for 28 years. Hum Genet (1996) 1.15
Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit (1993) 1.10
Imipramine treatment of painful diabetic neuropathy. JAMA (1984) 1.09
Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol (1996) 1.08
Are in-patient depressives more often of the melancholic subtype? Danish University Antidepressant Group. Acta Psychiatr Scand (1998) 1.08
Imipramine: clinical effects and pharmacokinetic variability. Psychopharmacology (Berl) (1977) 1.07
Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark. Br J Clin Pharmacol (1989) 1.06
Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype. Clin Pharmacol Ther (1986) 1.06
Femtosecond-laser ablation dynamics of dielectrics: basics and applications for thin films. Rep Prog Phys (2013) 1.06
Drug-related admissions to a department of medical gastroenterology. The role of self-medicated and prescribed drugs. Scand J Gastroenterol (1991) 1.04
Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol (1993) 1.04
Changes in the utilisation of lipid-lowering drugs over a 6-year period (1993-1998) in a Danish population. Eur J Clin Pharmacol (2001) 1.04
Drug related events and drug utilization in patients admitted to a geriatric hospital department. Dan Med Bull (1991) 1.03
Polypharmacy and the risk of drug-drug interactions among Danish elderly. A prescription database study. Dan Med Bull (1998) 1.02
Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin. Ther Drug Monit (1991) 1.01
Pain in general practice. Pain as a cause of patient-doctor contact. Scand J Prim Health Care (1986) 1.00
Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clin Pharmacol Ther (1990) 0.99
Drug related admissions to a cardiology department; frequency and avoidability. J Intern Med (1990) 0.98
Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians. Clin Pharmacol Ther (1996) 0.98
Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. Eur J Clin Pharmacol (1986) 0.98
Germination and outgrowth of Bacillus subtilis and Bacillus licheniformis spores in the gastrointestinal tract of pigs. J Appl Microbiol (2007) 0.98
Overdosage of antidepressants: clinical and pharmacokinetic aspects. Eur J Clin Pharmacol (1982) 0.97
Predictors of antiviral treatment initiation in hepatitis C virus-infected patients: a Danish cohort study. J Viral Hepat (2009) 0.97
First-pass metabolism of imipramine in man. Clin Pharmacol Ther (1975) 0.97
Psychopharmacological treatment and psychiatric morbidity in 390 cases of suicide with special focus on affective disorders. Acta Psychiatr Scand (2001) 0.96
Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates. Scand J Gastroenterol (1995) 0.96
Is overuse of sumatriptan a problem? A population-based study. Eur J Clin Pharmacol (1996) 0.96
The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther (1991) 0.96
First-pass metabolism of nortriptyline in man. Clin Pharmacol Ther (1975) 0.96
The analgesic effect of codeine as compared to imipramine in different human experimental pain models. Pain (2001) 0.96
Prehospital research and clinical decision-making. Eur J Emerg Med (1998) 0.95
Outpatient utilization of antidepressants: a prescription database analysis. J Affect Disord (1993) 0.94
Metacarpal morphometry in monozygotic dizygotic elderly twins. Calcif Tissue Res (1978) 0.94
Imipramine metabolites in blood of patients during therapy and after overdose. Clin Pharmacol Ther (1983) 0.94
Metabolism of tricyclic antidepressants. A review. Dan Med Bull (1974) 0.94
In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver. Drug Metab Dispos (1988) 0.93
Drug-related illness as a cause of admission to a department of respiratory medicine. Respiration (1992) 0.91
The hypoalgesic effect of imipramine in different human experimental pain models. Pain (1995) 0.91
Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator. Growth Horm IGF Res (2006) 0.91
Plasma levels and antidepressive effect of imipramine. Clin Pharmacol Ther (1976) 0.91
A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man. Br J Clin Pharmacol (1990) 0.91
Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms. A double-blind cross-over study. Br J Clin Pharmacol (1990) 0.90
Inappropriate use of sumatriptan: population based register and interview study. BMJ (1998) 0.90
Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man. Br J Clin Pharmacol (1990) 0.90